V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010692 | 330005453 | null | 71.1 | Curative (C) | 2014-06-24 | 2014-06-26 | Sunitinib | N | N | 330020530 | CAPECITABINE + VINORELBINE |
| 330010693 | 330005454 | 0 | null | Neo-adjuvant (N) | 2013-10-11 | 2013-10-11 | UKALL14- Intens/CNS Proph | N | N | 330020552 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 330010694 | 330005456 | 1.63 | 109 | Palliative (P) | 2017-10-16 | 2017-11-26 | Hydroxycarbamide | N | N | 330020556 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330010695 | 330005457 | 1.77 | 73.5 | Curative (C) | 2014-06-29 | 2014-06-29 | Cyclophosphamide High Dose | N | N | 330020565 | IPO |
| 330010696 | 330005461 | 1.7 | 54.3 | Curative (C) | 2018-03-26 | 2018-04-16 | AXI-STS TRIAL | 02 | N | 330020590 | CTD |
| 330010697 | 330008981 | 1.6 | 33.9 | Neo-adjuvant (N) | null | 2017-08-30 | Cyclophosphamide High Dose | N | N | 330020602 | CISPLATIN + FLUOROURACIL + RT |
| 330010698 | 330005466 | 1.77 | 53.2 | Disease modification (D) | 2018-01-25 | 2018-02-01 | LIPOSOMAL DAUNORUBICIN | null | N | 330020611 | HYDROXYCARBAMIDE |
| 330010700 | 330005468 | 1.53 | null | Neo-adjuvant (N) | 2013-11-01 | 2013-11-01 | IVA | N | N | 330020635 | TRIPLE INTRATHECAL |
| 330010702 | 330005471 | null | 36.4 | Curative (C) | 2017-03-20 | 2017-03-23 | AFATINIB | null | N | 330020665 | IDARUBICIN |
| 330010703 | 330005474 | 1.64 | 73.7 | Palliative (P) | 2018-06-03 | 2018-06-13 | AML18 PILOT TRIAL | N | N | 330020669 | CVP R |
| 330010705 | 330005479 | 1.59 | null | Palliative (P) | 2014-03-29 | 2014-04-01 | Gemcitabine + Capecitabine | 02 | N | 330020693 | DASATINIB |
| 330010706 | 330005481 | 1.63 | 58 | Palliative (P) | 2015-12-08 | 2016-01-02 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 330020694 | NILOTINIB |
| 330010707 | 330005482 | null | 62.3 | Palliative (P) | 2017-03-20 | 2017-04-19 | CARBOPLATIN + VINCRISTINE | 2 | N | 330020710 | MITOTANE |
| 330010708 | 330008990 | 1.65 | 92.2 | Curative (C) | 2017-04-18 | 2017-04-18 | Ifosfamide | N | N | 330020722 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 330010709 | 330011918 | null | 64 | Palliative (P) | 2017-10-08 | 2017-12-15 | Dacarbazine | Y | N | 330020731 | CAPECITABINE + VINORELBINE |
| 330010710 | 330005486 | 0 | 61 | Curative (C) | null | 2013-04-09 | Cytarabine+Methotrexate Intrathecal | null | N | 330020733 | CISPLATIN + TOPOTECAN |
| 330010711 | 330005489 | 1.8 | null | Disease modification (D) | 2015-07-23 | 2015-08-15 | Cyclophosphamide High Dose | N | N | 330020737 | BORTEZOMIB |
| 330010712 | 330008992 | 1.78 | 66.6 | Palliative (P) | 2013-03-12 | 2014-06-19 | Dacarbazine | N | N | 330020744 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330010714 | 330005494 | 0 | 79 | Curative (C) | 2017-07-13 | 2017-07-14 | UKALL14- Ph 2 Induction | N | N | 330020814 | BENDAMUSTINE |
| 330010715 | 330005496 | 1.69 | 95 | Curative (C) | 2013-12-02 | 2014-05-25 | AML 19 TRIAL | N | N | 330020832 | CARBOPLATIN + CETUXIMAB |
| 330010716 | 330005498 | 1.81 | 69.6 | Curative (C) | 2014-08-25 | 2014-09-29 | BEP 5 Day | 2 | N | 330020835 | CAPECITABINE + CISPLATIN |
| 330010718 | 330005501 | 0 | null | Curative (C) | 2013-07-03 | 2013-12-30 | AML 18 TRIAL | N | N | 330020894 | CAPECITABINE + CISPLATIN |
| 330010719 | 330009001 | 1.76 | 41.5 | Curative (C) | null | 2017-04-10 | CVP R | N | null | 330020902 | DACTINOMYCIN + CYCLO + VINCRISTINE |
| 330010720 | 330005505 | null | 57.1 | Neo-adjuvant (N) | 2014-11-14 | 2014-11-14 | Cyclophosphamide PO +Vinorelbine IV | N | N | 330020923 | IFOSFAMIDE |
| 330010721 | 330005508 | 1.38 | 44 | Palliative (P) | 2017-11-13 | 2017-11-17 | UKALL14- Ph 1 Induction | N | N | 330020955 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010722 | 330005509 | 1.58 | 9.5 | Neo-adjuvant (N) | 2015-04-15 | 2015-04-15 | Ifosfamide | 2 | N | 330020955 | EMA/CO |
| 330010723 | 330005510 | 1.61 | 71.4 | Curative (C) | 2015-08-08 | 2015-12-01 | DHAP | N | N | 330020977 | DACTINOMYCIN + CYCLO + VINCRISTINE |
| 330010724 | 330010882 | 1.64 | 50.7 | Palliative (P) | 2018-03-30 | 2018-04-08 | PAC-PLAT | N | N | 330020984 | FLUOROURACIL + MITOMYCIN |
| 330010725 | 330005515 | 1.84 | 84.5 | Curative (C) | 2016-06-20 | 2016-07-09 | Capecitabine + Cisplatin | N | null | 330020988 | CARBOPLATIN + CETUXIMAB + FU |
| 330010726 | 330005516 | 1.73 | 87 | Palliative (P) | 2014-06-09 | 2014-06-16 | UKALL14- Ph 2 Induction + Imatinib | N | N | 330020998 | SUNITINIB |
| 330010727 | 330012521 | 1.64 | null | Palliative (P) | 2014-11-23 | 2014-11-23 | VINCRISTINE | 02 | N | 330021007 | BORTEZOMIB + RITUXIMAB |
| 330010728 | 330005518 | 1.5 | null | Neo-adjuvant (N) | 2012-10-08 | 2013-09-07 | Triple Intrathecal | 02 | N | 330021026 | CARBOPLATIN + CETUXIMAB + FU |
| 330010729 | 330005520 | 1.72 | 64 | Curative (C) | 2015-09-09 | 2015-09-11 | Cladribine (subcut) 5 days | 2 | N | 330021030 | BUSULFAN + MELPHALAN |
| 330010731 | 330005523 | null | null | Palliative (P) | 2017-07-27 | 2017-08-07 | PEMBROLIZUMAB | 02 | N | 330021050 | DACTINOMYCIN + VINCRISTINE |
| 330010732 | 330005524 | null | 85.7 | Neo-adjuvant (N) | null | 2014-07-16 | Cyclophosphamide High Dose | Y | N | 330021056 | DOXORUBICIN + IFOSFAMIDE |
| 330010733 | 330009013 | 0 | null | Palliative (P) | 2019-04-02 | 2019-04-02 | DHAP | 02 | N | 330021058 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 330010734 | 330009013 | 1.41 | 109 | null | 2014-12-05 | 2015-01-16 | R GCVP | null | N | 330021058 | PAC-PLAT |
| 330010735 | 330005527 | 1.52 | 65 | Neo-adjuvant (N) | 2014-07-12 | 2014-07-25 | IMATINIB | N | N | 330021093 | CETUXIMAB + CISPLATIN + FU |
| 330010736 | 330013079 | 1.6 | 74.2 | null | null | 2014-11-18 | MELPHALAN + TREOSULPHAN | 02 | N | 330021096 | TRASTUZUMAB |
| 330010738 | 330005537 | 1.52 | 54.6 | Palliative (P) | 2014-09-22 | 2015-06-23 | BORTEZOMIB + THALIDOMIDE | N | N | 330021119 | IVA |
| 330010739 | 330005538 | 1.82 | null | Palliative (P) | 2016-12-20 | 2017-04-22 | Cetuximab+Cisplatin+FU (> Cycle 2) | 02 | null | 330021120 | BEP |
| 330010740 | 330009024 | 1.52 | 56.8 | Curative (C) | 2017-01-13 | 2017-01-19 | Alemtuzumab + Cyclophos TBI Allo | 2 | N | 330021153 | BUSULFAN + MELPHALAN |
| 330010741 | 330005546 | 1.03 | 77.95 | Curative (C) | 2016-11-06 | 2017-01-09 | AML 18 TRIAL | N | null | 330021212 | GDP |
| 330010742 | 330012525 | 1.7 | 60.5 | Palliative (P) | 2016-08-09 | 2016-08-09 | Docetaxel + Trastuzumab (Maint) | N | N | 330021215 | UKALL 2011 |
| 330010743 | 330005550 | 1.76 | null | Neo-adjuvant (N) | 2016-04-22 | 2016-10-29 | Mitotane 5.5 - 10g | 02 | N | 330021284 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330010744 | 330005552 | 1.61 | 119 | Curative (C) | 2017-08-03 | 2017-08-03 | BORTEZOMIB + THALIDOMIDE | 2 | N | 330021288 | THALIDOMIDE |
| 330010745 | 330005555 | 0 | 73.6 | Palliative (P) | 2015-07-02 | 2015-08-20 | CHOP R - 21 days | 2 | null | 330021301 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 330010746 | 330005555 | 2 | 73.5 | Curative (C) | 2016-04-27 | 2016-05-31 | CNS LGG Irinotecan & Bevacizumab | Y | N | 330021301 | LENALIDOMIDE |
| 330010747 | 330005555 | 1.75 | 57.2 | Neo-adjuvant (N) | null | 2014-01-17 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 02 | null | 330021301 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330010748 | 330005558 | 1.57 | 20.1 | Palliative (P) | 2016-11-30 | 2017-01-08 | VIDE | null | null | 330021311 | VIDE |